Phase 3 Clinical Trial of Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2(Trafermin)

NCT00734708 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

328

Enrollment

INDUSTRY

Sponsor class

Conditions

Periodontitis
Alveolar Bone Loss
Periodontal Attachment Loss

Interventions

DRUG: Trafermin (genetical recombination)
DRUG: Placebo

Sponsor

Kaken Pharmaceutical